Why might thiazolidinediones increase exercise capacity in patients with type 2 diabetes?

Diabetes Care

Volumn 28, Issue 12, 2005, Pages 2975-2977

  LeBrasseur, Nathan K ^a   Ruderman, Neil B ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; ROSIGLITAZONE; SUCCINATE DEHYDROGENASE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

DIET; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; EXERCISE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MITOCHONDRION; MUSCLE BLOOD FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PROTEIN BINDING; VASODILATATION; ADULT; BLOOD; FITNESS; MIDDLE AGED; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; DIABETES MELLITUS, TYPE 2; EXERCISE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; OXYGEN CONSUMPTION; PHYSICAL FITNESS; THIAZOLIDINEDIONES;

EID: 33644832972     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.12.2975     Document Type: Editorial

References (26)

1. Saltin B, Houston M, Nygaard E, Graham T, Wahren J: Muscle fiber characteristics in healthy men and patients with juvenile diabetes. Diabetes 28 (Suppl 1):93-99, 1979
2. Schneider SH, Amorosa LF, Khachadurian AK, Ruderman NB: Studies on the mechanism of improved glucose control during regular exercise in type 2 (noninsulin-dependent) diabetes. Diabetologia 26:355-360, 1984
3. Regensteiner JG, Bauer TA, Reusch JEB: Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. Diabetes Care 28:2877-2883, 2005
4. He J, Watkins S, Kelley DE: Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50:817-823, 2001
5. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-2950, 2002
6. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE: Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54:8-14, 2005
7. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 34:267-273, 2003
8. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100:8466-8471, 2003
9. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy M-A, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695-1701, 1998
10. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610, 1996
11. Clark MG, Rattigan S, Clerk LH, Vincent MA, Clark AD, Youd JM, Newman JM: Nutritive and non-nutritive blood flow: rest and exercise. Acta Physiol Scand 168:519-530, 2000
12. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327, 1997
13. Unger RH: Lipotoxic diseases. Annu Rev Med 53:319-336, 2002
14. Rajala MW, Scherer PE: Minireview: the adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-3773, 2003
15. Ruderman N, Prentki M: AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3:340-351, 2004
16. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974, 2002
17. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021-45026, 2003
18. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y: Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 277:37487-37491, 2002
19. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005-2010, 2001
20. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91-100, 2003
21. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB: Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 99:16309-16313, 2002
22. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
23. Tomas E, Kelly M, Xiang X, Tsao TS, Keller C, Keller P, Luo Z, Lodish H, Saha AK, Unger R, Ruderman NB: Metabolic and hormonal interactions between muscle and adipose tissue. Proc Nutr Soc 63:381-385, 2004
24. Fryer LG, Parbu-Patel A, Carling D: The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226-25232, 2002
25. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB: AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320:449-454, 2004
26. Yu X, McCorkle S, Wang M, Lee Y, Li J, Saha AK, Unger RH, Ruderman NB: Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 47:2012-2021, 2004